Clene Provides Update On Its NIH-Funded Expanded Access Program For CNM-Au8® In ALS (ACT-EAP)
National Institutes Of Health United States Salt Lake City Kevin Gardner Jinsya Andrews David Schull
Source: menafn.com
📰 Rob Etherington News
Rob Etherington News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Rob Etherington. Real-time updates on events, politics, business and more.
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
Initiated discussions with FDA regarding accelerated approval pathway for CNM-Au8® for the treatment of ALS with the objective of submitting an NDA in 2024Released long-term data from the open-label extension
National Institutes Of Health United States Salt Lake City Rob Etherington Clene Nanomedicine Clene Inc
Source: eagletribune.com
Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
SALT LAKE CITY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference. Rob Etherington, Chief Executive Officer, and Morgan Brown, Chief Financial Officer, will participate in t...
Source: yahoo.com
Clene's CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial
CNM-Au8® treatment demonstrated significantly reduced plasma neurofilament light chain levels compared to placebo at 24 weeks Clene plans to discuss the totality of the survival and time-to-event... | June 16, 2023
Source: marketscreener.com
Clene Reports First Quarter 2023 Financial Results and
ALS biomarker and long-term clinical data expected mid-yearNeurology expert Ben Greenberg, M.D., M.H.S., joined as Head of Medical SALT LAKE CITY, May ...
Source: globenewswire.com
ALS and MS Clinical Data from Clene's CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting
SALT LAKE CITY, April 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) a...
Source: sina.com.hk
Clene Nanomedicine wins $5 million Maryland grant
ELKTON — As work continues toward completion of a manufacturing facility for Clene Nanomedicine, Inc. in the Chesapeake Corporate Center, the Maryland Department of Housing and Community Development has awarded
United States Larry Hogan Mark Mortenson Clene Nanomedicine Rob Etherington Chesapeake Corporate Center
Source: cecildaily.com
Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28
SALT LAKE CITY, June 27, 2022 -- Clene Inc. along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company... | June 27, 2022
Source: marketscreener.com